• 专利标题:   Preparing graphene oxide-based composite nanofiltration membrane involves weighing sodium hyaluronate powder and dissolving in phosphate buffer, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide or N-hydroxysuccinimide powder, and dissolving mono-6-aminodeoxy-beta-cyclodextrin.
  • 专利号:   CN115178106-A
  • 发明人:   SHAO R, PEI X, LIU S, WU J, XU Z, ZHU B, LI N
  • 专利权人:   UNIV TIANJIN POLYTECHNIC
  • 国际专利分类:   B01D061/02, B01D069/12, B01D071/02
  • 专利详细信息:   CN115178106-A 14 Oct 2022 B01D-069/12 202202 Chinese
  • 申请详细信息:   CN115178106-A CN10733224 28 Jun 2022
  • 优先权号:   CN10733224

▎ 摘  要

NOVELTY - Preparing graphene oxide-based composite nanofiltration membrane involves weighing 0.2 millimol of sodium hyaluronate powder and dissolving in phosphate buffer, then adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide powder with a molar ratio of 1:1. The 0.5 millimol of mono-6-aminodeoxy-beta-cyclodextrin is weighed and dissolved in phosphate buffer, then added to the sodium hyaluronate solution. The dialysis bag with a molecular weight of 2000 dalton is used for dialysis for 5 days, and taken the liquid in the dialysis bag and freeze-dried to obtain sodium hyaluronate/β-cyclodextrin compound powder. The 200 mg of graphene oxide (GO) powder is weighed in 100 ml of deionized water and dispersed by ultrasonic, and adjusted the pH to 9.0 with boric acid buffer. The 2 g of amantadine is added to the graphene oxide suspension and fully dissolved, and the reaction is continuously stirred at 40℃ for 24 hours. USE - Method for preparing graphene oxide-based composite nanofiltration membrane. ADVANTAGE - The prepared composite nanofiltration membrane has excellent separation performance and permeability, and the synthesis process is simple, which provides certain technical guidance for the preparation of high-performance graphene oxide-based composite nanofiltration membrane. DETAILED DESCRIPTION - Preparing graphene oxide-based composite nanofiltration membrane involves weighing 0.2 millimol of sodium hyaluronate powder and dissolving in phosphate buffer, then adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide powder with a molar ratio of 1:1. The 0.5 millimol of mono-6-aminodeoxy-beta-cyclodextrin is weighed and dissolved in phosphate buffer, then added to the sodium hyaluronate solution. The dialysis bag with a molecular weight of 2000 dalton is used for dialysis for 5 days, and taken the liquid in the dialysis bag and freeze-dried to obtain sodium hyaluronate/β-cyclodextrin compound powder. The 200 mg of graphene oxide (GO) powder is weighed in 100 ml of deionized water and dispersed by ultrasonic, and adjusted the pH to 9.0 with boric acid buffer. The 2 g of amantadine is added to the graphene oxide suspension and fully dissolved, and the reaction is continuously stirred at 40℃ for 24 hours. The final reactant is centrifuged, removed the supernatant, added deionized water, and performed centrifugation, and finally lyophilized to obtain adamantane/graphene oxide powder. The sodium hyaluronate/β-cyclodextrin powder and adamantane/graphene oxide powder are weighed in water and ultrasonically to obtain a uniform dispersion, and placed in a conical flask for use, where the mass ratio of sodium hyaluronate/β-cyclodextrin to adamantane/graphene oxide does not exceed 10. The dispersion liquid is pumped onto the polymer-based membrane by a vacuum filtration device for self-assembly into a membrane, and naturally dried to obtain a novel graphene oxide-based composite nanofiltration membrane, where the loading amount of the graphene oxide membrane is 10-25 ml.